Chiosis G - Search Results

1

Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.

Taldone T, Patel PD, Patel M, Patel HJ, Evans CE, Rodina A, Ochiana S, Shah SK, Uddin M, Gewirth D, Chiosis G. Taldone T, et al. Among authors: chiosis g. J Med Chem. 2013 Sep 12;56(17):6803-18. doi: 10.1021/jm400619b. Epub 2013 Aug 21. J Med Chem. 2013. PMID: 23965125 Free PMC article.

2

LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family.

Chiosis G, Rosen N, Sepp-Lorenzino L. Chiosis G, et al. Bioorg Med Chem Lett. 2001 Apr 9;11(7):909-13. doi: 10.1016/s0960-894x(01)00099-3. Bioorg Med Chem Lett. 2001. PMID: 11294389

3

A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells.

Chiosis G, Timaul MN, Lucas B, Munster PN, Zheng FF, Sepp-Lorenzino L, Rosen N. Chiosis G, et al. Chem Biol. 2001 Mar;8(3):289-99. doi: 10.1016/s1074-5521(01)00015-1. Chem Biol. 2001. PMID: 11306353

4

Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function.

Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N. Basso AD, et al. Among authors: chiosis g. J Biol Chem. 2002 Oct 18;277(42):39858-66. doi: 10.1074/jbc.M206322200. Epub 2002 Aug 9. J Biol Chem. 2002. PMID: 12176997 Free article.

5

Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase.

Chiosis G, Lucas B, Shtil A, Huezo H, Rosen N. Chiosis G, et al. Bioorg Med Chem. 2002 Nov;10(11):3555-64. doi: 10.1016/s0968-0896(02)00253-5. Bioorg Med Chem. 2002. PMID: 12213470

6

Development of purine-scaffold small molecule inhibitors of Hsp90.

Chiosis G, Lucas B, Huezo H, Solit D, Basso A, Rosen N. Chiosis G, et al. Curr Cancer Drug Targets. 2003 Oct;3(5):371-6. doi: 10.2174/1568009033481778. Curr Cancer Drug Targets. 2003. PMID: 14529388 Review.

7

Synthesis of novel fluorescent probes for the molecular chaperone Hsp90.

Llauger-Bufi L, Felts SJ, Huezo H, Rosen N, Chiosis G. Llauger-Bufi L, et al. Among authors: chiosis g. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3975-8. doi: 10.1016/j.bmcl.2003.08.065. Bioorg Med Chem Lett. 2003. PMID: 14592488

8

Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90.

Vilenchik M, Solit D, Basso A, Huezo H, Lucas B, He H, Rosen N, Spampinato C, Modrich P, Chiosis G. Vilenchik M, et al. Among authors: chiosis g. Chem Biol. 2004 Jun;11(6):787-97. doi: 10.1016/j.chembiol.2004.04.008. Chem Biol. 2004. PMID: 15217612

9

Development of a fluorescence polarization assay for the molecular chaperone Hsp90.

Kim J, Felts S, Llauger L, He H, Huezo H, Rosen N, Chiosis G. Kim J, et al. Among authors: chiosis g. J Biomol Screen. 2004 Aug;9(5):375-81. doi: 10.1177/1087057104265995. J Biomol Screen. 2004. PMID: 15296636

10

Hsp90: the vulnerable chaperone.

Chiosis G, Vilenchik M, Kim J, Solit D. Chiosis G, et al. Drug Discov Today. 2004 Oct 15;9(20):881-8. doi: 10.1016/S1359-6446(04)03245-3. Drug Discov Today. 2004. PMID: 15475321 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

179 results

Search Page

Filters